Clinical Trials Latin America

Clinical Trials Latin America

$995.00

As R&D costs rise exponentially and trial subjects grow scarce in the US and Europe, life sciences firms are turning to the emerging markets to supplement patient enrollment — and to reduce costs.

Latin America holds about 1/10 of the number of trials of the United States, and Brazil, numbered among the high-profile BRIC market, receives the lion’s share of attention. But savvy companies leverage other nations’ untapped promise: patient availability, advanced knowledge and infrastructure, and ease of communication. These advantages are cultivated in an environment open to clinical development, but scores of questions can create reams of data – and misperceptions – and potentially keep teams away.

Eliminate information clutter and zero in on the key clinical research in emerging markets of Latin America.

  • Description
  • Additional information

REPORT HIGHLIGHTS

Clinical Trials Latin America

  • Publication Date: November 2010
  • Pages: 189
  • Chapters: 3
  • Metrics: 400+
  • Charts/Graphics: 100+
  • Profiles: 12

Data split by following countries:

  • Brazil
  • Argentina
  • Mexico
  • Other Latin American Countries
Report Features

Pick the right market for clinical trials in Latin America by comparing costs, timelines, regulatory environments and problem areas across countries as you discover unique benefits to each. Explore ratings for 13 elements of trial success. Accelerate patient recruitment and retention by targeting markets for treatment-naive patients, and discover the factors to ensure easy recruitment and strong retention.

Reason to Buy

Eliminate information clutter and zero in on the key emerging markets in Latin America. Access primers on individual countries that include time- and cost savings benchmarks and rankings data while learning from others’ first-hand experiences to reap the benefits of the region. Latin America holds about 1/10 of the number of trials of the United States, and Brazil, numbered among the high-profile BRIC market, receives the lion’s share of attention. But savvy companies leverage other nations’ untapped promise: patient availability, advanced knowledge and infrastructure, and ease of communication. These advantages are cultivated in an environment open to clinical development, but scores of questions can create reams of data — and misconceptions — and potentially keep teams away.

Target Audience

Executives, directors, and managers involved in the following areas should consider purchasing this report:
– Clinical development
– Site/Trial Management
– Patient Recruitment
– Strategic planning groups
– Contract Research Organizations (CROs)
– Strategic Planning

Chapter Example

While clinical trials in Argentina are cheaper than trials in the US, survey data show that running trials in Argentina ends up being more time-consuming. This is likely due to Argentina’s very slow-moving regulatory environment. As ANMAT is able to decrease regulatory timelines required for pharmaceutical companies to move forward, it should become less of a problem. As one interviewee noted, the problem stems from the age-old law of supply and demand: agencies need to increase their resources to deal with the many submissions before regulatory timelines can shorten. A consultant from a large pharma company, however, said that the time spent waiting for regulatory approval was not worth the wait, and the company ended up cutting its losses in 2008 and pulling out of the country before the trial could begin. This interviewee discussed the confusion and frustration revolving around the complicated regulatory process by stating: “Contact with the regulatory authority agency is not very easy. It is difficult to understand why [the approval process] takes so long. And in the case of no approval, it is not easy to obtain more information, to change the protocol, or to provide an amendment.” Since communication and access with the agency was so difficult, ultimately, the interviewee did not move forward with the trial.